This trial is active, not recruiting.

Condition coronary artery disease
Sponsor Brigham and Women's Hospital
Start date January 2012
End date January 2016
Trial size 400 participants
Trial identifier NCT01821924, 2011P000643


The investigators plan to use retrospective data to assess heart function and structure abnormalities through the use of an approved vasodilating agent for stress cardiac MRI tests. The investigators are interested in how these MRI findings relate to long-term prognosis in people who are at risk for cardiac disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective

Primary Outcomes

All-cause mortality, MI, heart failure hospitalization or documentation of an LV ejection fraction < 0.40 after index CMR at a follow-up.
time frame: 5 years

Eligibility Criteria

Male or female participants at least 21 years old.

Inclusion Criteria: - Age >/= 21 years old - No contraindications for cardiac MRI (by renal function or metallic hazards)

Trial information was received from ClinicalTrials.gov and was last updated in March 2013.
Information provided to ClinicalTrials.gov by Brigham and Women's Hospital.